Pivikto (Alpelisib) 150mg 28 Tablets | Novartis India Original | GLT

Generic Information: Pivikto (Alpelisib) — Novartis India Original

Pivikto is the India-market brand of originator alpelisib from Novartis — not a licensed copy, but the same company's product sold under a different name in a different market, exactly as Keytruda and other originators carry local brand names across Asia. The carton GLT supplies holds 28 film-coated tablets of 150 mg, and the box says plainly what it is: "For oral use only... FOR SALE IN INDIA ONLY", with the dosing reminder printed on the pack — one 150 mg tablet plus one 150 mg tablet equals the 300 mg daily dose. India matters because it is one of the very few markets where the originator company itself sells this medicine at Indian-market terms, which reshapes the economics of treatment entirely.

What Is Pivikto (Alpelisib) Used For?

Pivikto treats HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer in combination with fulvestrant, after progression on a prior endocrine-based regimen, in postmenopausal women and in men. Indian oncology practice tracks the international label here, and Indian testing labs — tissue and liquid biopsy both — routinely confirm PIK3CA status before the first prescription. About 40% of HR+/HER2- advanced breast cancers carry the mutation, which is why testing is not optional paperwork but the actual key to whether the drug can help.

How Does Pivikto (Alpelisib) Work?

Alpelisib is a selective PI3K alpha inhibitor: it shuts down the growth pathway that the mutated PIK3CA gene keeps running, while fulvestrant removes the estrogen receptor the tumor relies on. The combination's evidence is the SOLAR-1 trial — progression-free survival nearly doubled to 11.1 months versus 5.7 months, and median overall survival gained 7.9 months in PIK3CA-mutated patients. Every Pivikto tablet carries that same molecular pharmacology; the brand name is the only thing India changed.

Indications of Pivikto (India)

The Indian label covers the same core use as the global Piqray label: PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer, with fulvestrant, after endocrine progression. It is a distinct product from Novartis' Vijoice brand — the PROS (rare overgrowth syndrome) indication and its pediatric dosing belong to that other brand and product line, and the two are not interchangeable.

Dosage and Administration

The standard schedule is 300 mg once daily — two 150 mg tablets swallowed whole with food each morning, which is exactly the pack's printed reminder ("1 × 150 mg + 1 × 150 mg = 300 mg"). At that schedule one 28-tablet carton covers 14 days, so a treatment month means two cartons. For toxicity the dose steps down to 250 mg daily and then 200 mg daily under the oncologist's direction. Fulvestrant follows its own calendar — 500 mg intramuscularly on days 1, 15 and 29, then monthly. A missed dose may be taken with food within nine hours; after that it is skipped, and vomiting is not a reason to re-dose.

Side Effects of Pivikto

The class profile applies unchanged: hyperglycemia is the most characteristic effect (fasting glucose and HbA1c checked before starting and monitored through treatment), with diarrhea, stomatitis, rash, fatigue and appetite loss commonly reported, and creatinine and liver enzymes drifting on labs. Serious but infrequent risks include severe hypersensitivity, severe skin reactions such as Stevens-Johnson syndrome, pneumonitis and embryo-fetal toxicity — contraception during and for a period after therapy is required. Indian treatment protocols manage these exactly as international ones do: early reporting, glucose control, dose holds, and stepwise reduction before any thought of stopping.

Storage Instructions

Store below 30°C in the original carton, protected from light and moisture — realistic in South Asian climates if the box stays out of direct sun and humid rooms. Keep blisters sealed until use, store out of children's reach, and dispose of expired tablets at a pharmacy.

Why Choose Pivikto from GLT?

For buyers comparing the cost of originator alpelisib across markets, India is usually the answer: the same Novartis molecule at Indian-market terms lands at a fraction of US and European pricing — often cited as the most affordable genuine original alpelisib in the world. GLT supplies sealed Pivikto cartons with the India-only packaging intact (a point of authenticity, not a flaw), batch documentation, and pre-shipment photographs on request. We serve individual patients and institutional tenders alike, and a human being — not a ticketing system — answers on WhatsApp +86 15234153837 and [email protected]. If Indian channel supply is constrained, we will say so and quote the German or Hong Kong original, or a certified generic, side by side.

How to Order Pivikto (Alpelisib)

Write to GLT on WhatsApp +86 15234153837 or at [email protected] with the quantity and pack sizes you need. We reply with a formal quotation, courier options and payment details — typically within one working day — and dispatch sealed stock with complete export paperwork on confirmation. Monthly recurring supply can be scheduled in advance; institutions can request CoA copies and batch photographs before committing.

FAQ

Is Pivikto the same as Piqray? Yes in substance — both are Novartis originator alpelisib; Pivikto is the brand name used in India with India-market packaging and pricing. The clinical evidence base is shared.

Why does the box say "FOR SALE IN INDIA ONLY"? It is Novartis' distribution statement for the Indian market — proof of a genuine India-channel original. GLT exports it with full paperwork for personal and institutional use abroad.

How many cartons per month? Two. The 28-tablet carton is a 14-day supply at the standard two-tablets-per-morning dose, so a treatment month is 56 tablets of 150 mg.

Is it cheaper than the German or HK original? Substantially, as a rule — Indian-market terms make it the lowest-priced genuine original alpelisib in most comparisons; ask us for a current side-by-side quotation.

Can Pivikto be used for PROS? No — the PROS indication and its dosing belong to the Vijoice brand line. Breast cancer and PROS are treated with different schedules even though the molecule is shared.